NeoPred, a dual-phase CT AI tool, accurately predicts major pathological response in NSCLC patients preoperatively.
Key Details
- 1NeoPred combines pre-treatment and pre-surgery CT scans with clinical data to predict major pathological response (MPR) in NSCLC undergoing neoadjuvant chemo-immunotherapy.
- 2Study included 509 patients across four oncology centers (459 retrospective, 50 prospective, 59 external validation).
- 3NeoPred reached AUCs of 0.772 (imaging only) and 0.787 (imaging plus clinical data) on external validation, outperforming thoracic surgeons (AUC 0.760 vs 0.720) in prospective testing.
- 4AI support improved surgeons' AUC to 0.829 and diagnostic accuracy to 82%.
- 5NeoPred identified 'pseudo-stable' responders missed by standard RECIST criteria, with AUCs of 0.742 (external) and 0.833 (prospective).
Why It Matters
Accurately predicting response before surgery could enable earlier, evidence-based clinical decisions for NSCLC, reducing overtreatment and personalizing care. This work demonstrates the expanding role and performance advantage of AI-assisted imaging over traditional assessment in complex oncologic management.
Source
EurekAlert
Related News
•EurekAlert
Sybil AI Model Accurately Predicts Lung Cancer Risk in Diverse Urban Populations
A new study validates the Sybil AI model for predicting lung cancer risk using low-dose CT in a predominantly Black cohort at an urban safety-net hospital.
•EurekAlert
AI and Imaging Reveal Atomic Order in 2D Nanomaterials
A multi-university team has uncovered how atomic order and disorder in 2D MXene nanomaterials can be predicted and tailored using AI, enabled by advanced imaging analysis.
•EurekAlert
DreamConnect AI Translates and Edits fMRI Brain Activity into Images
Researchers unveil DreamConnect, an AI system that reconstructs and edits visual imagery from fMRI brain data with language prompts.